A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancer
We performed a systematic review of phase I trials specifically conducted for patients with head and neck squamous cell carcinoma published between January 1, 2008 and August 31, 2023. PubMed and Cochrane Library databases were searched using a combination of terms: “((head and neck) OR (head &a...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-09-01
|
| Series: | Oral Oncology Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024004345 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553704415657984 |
|---|---|
| author | V.G. Espeli A. Gomez P. Balermpas G. Treglia A. Stathis |
| author_facet | V.G. Espeli A. Gomez P. Balermpas G. Treglia A. Stathis |
| author_sort | V.G. Espeli |
| collection | DOAJ |
| description | We performed a systematic review of phase I trials specifically conducted for patients with head and neck squamous cell carcinoma published between January 1, 2008 and August 31, 2023. PubMed and Cochrane Library databases were searched using a combination of terms: “((head and neck) OR (head & neck)) AND ((cancer*) OR (tumor*) OR (tumour*) OR (neoplasm*) OR (carcinoma*) OR (malignan*)) AND ((phase 1) OR (phase I))''to identify phase I dose-finding trials including a majority of lymphoma patients.Eighty-five trials (H&N patients N = 1714) were included. Among them, 53 trials complying with inclusion/exclusion criteria and were included in the current analysis: 32 (60 %) enrolled only patients with head and neck cancer, while 21 (40 %) included also patients with other solid tumors.The median rate of grade 3-4 adverse events was 41 %. With regards to clinical activity, the median response rate (RR) was 16 %, which is in line with the usually reported rate for phase I trials enrolling unselected populations of patients with solid tumors. |
| format | Article |
| id | doaj-art-d40de0b582204790b7234018a5108982 |
| institution | Kabale University |
| issn | 2772-9060 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Oral Oncology Reports |
| spelling | doaj-art-d40de0b582204790b7234018a51089822025-01-09T06:16:50ZengElsevierOral Oncology Reports2772-90602024-09-0111100588A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancerV.G. Espeli0A. Gomez1P. Balermpas2G. Treglia3A. Stathis4Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Corresponding author.Oncology Institute of Southern Switzerland, EOC, Bellinzona, SwitzerlandDepartment of Radiation Oncology, Zurich University Hospital, Zurich, SwitzerlandClinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Lugano, SwitzerlandOncology Institute of Southern Switzerland, EOC, Bellinzona, SwitzerlandWe performed a systematic review of phase I trials specifically conducted for patients with head and neck squamous cell carcinoma published between January 1, 2008 and August 31, 2023. PubMed and Cochrane Library databases were searched using a combination of terms: “((head and neck) OR (head & neck)) AND ((cancer*) OR (tumor*) OR (tumour*) OR (neoplasm*) OR (carcinoma*) OR (malignan*)) AND ((phase 1) OR (phase I))''to identify phase I dose-finding trials including a majority of lymphoma patients.Eighty-five trials (H&N patients N = 1714) were included. Among them, 53 trials complying with inclusion/exclusion criteria and were included in the current analysis: 32 (60 %) enrolled only patients with head and neck cancer, while 21 (40 %) included also patients with other solid tumors.The median rate of grade 3-4 adverse events was 41 %. With regards to clinical activity, the median response rate (RR) was 16 %, which is in line with the usually reported rate for phase I trials enrolling unselected populations of patients with solid tumors.http://www.sciencedirect.com/science/article/pii/S2772906024004345 |
| spellingShingle | V.G. Espeli A. Gomez P. Balermpas G. Treglia A. Stathis A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancer Oral Oncology Reports |
| title | A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancer |
| title_full | A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancer |
| title_fullStr | A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancer |
| title_full_unstemmed | A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancer |
| title_short | A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancer |
| title_sort | systematic review of contemporary phase i trials in patients with recurrent metastatic head and neck cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2772906024004345 |
| work_keys_str_mv | AT vgespeli asystematicreviewofcontemporaryphaseitrialsinpatientswithrecurrentmetastaticheadandneckcancer AT agomez asystematicreviewofcontemporaryphaseitrialsinpatientswithrecurrentmetastaticheadandneckcancer AT pbalermpas asystematicreviewofcontemporaryphaseitrialsinpatientswithrecurrentmetastaticheadandneckcancer AT gtreglia asystematicreviewofcontemporaryphaseitrialsinpatientswithrecurrentmetastaticheadandneckcancer AT astathis asystematicreviewofcontemporaryphaseitrialsinpatientswithrecurrentmetastaticheadandneckcancer AT vgespeli systematicreviewofcontemporaryphaseitrialsinpatientswithrecurrentmetastaticheadandneckcancer AT agomez systematicreviewofcontemporaryphaseitrialsinpatientswithrecurrentmetastaticheadandneckcancer AT pbalermpas systematicreviewofcontemporaryphaseitrialsinpatientswithrecurrentmetastaticheadandneckcancer AT gtreglia systematicreviewofcontemporaryphaseitrialsinpatientswithrecurrentmetastaticheadandneckcancer AT astathis systematicreviewofcontemporaryphaseitrialsinpatientswithrecurrentmetastaticheadandneckcancer |